Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Sweden / NCT06261411
Active, not recruiting Not applicable

Lung Ultrasound as Alternative to Radiography in Thoracic Surgery

NCT06261411 · tracked via the Priya Life Science Sweden tracker
Sponsor
Uppsala University Hospital
Phase
Not applicable
Started
2024-02-12
Last updated
2025-04-29

Condition(s) studied

Thoracic SurgeryUltrasonography

Investigational drug(s) / intervention(s)

Lung Ultrasound

Lung Ultrasound: Diagnostic ultrasound of pulmonary tissues such as pleura, plural spaces, and parenchyma.

Study summary

This projects aim is to study the effects of substitute conventional chest x-ray with lung ultrasound for patients undergoing thoracic surgery.

Participants in the study will be randomized to either ultrasound or routine chest x-ray as the primary method of diagnosis after having received surgery to their lungs.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Segmental, partial, or wedge resection lung surgery, or lobectomy. * Written informed consent * Available research team for measurements. Exclusion Criteria: * Pregnancy * Re-surgery due to complications related to the original surgery * Need for critical care or admittance to the ICU. * Patient or physician choice of withdrawal from the study

Primary outcome measure(s)

  • Reduction in chest x-ray — Through patient hospital stay, an average of five days
    Reduction in chest x-ray in patients undergoing thoracic surgery when LUS is the primary method of investigation.

Trial sites (1)

FacilityCityRegionStatus
Uppsala Akademiska sjukhuset Uppsala Uppland

More Uppsala University Hospital trials in Sweden

Swedish National Parotidectomy Study (SNaPs): Drainless Versus Standard Surgery Recruiting
Mesenchymal Stromal Cells to Treat Type 1 Diabetes in Children and Adolescents Active, not recruiting
Postoperative Pain in Infants Starting soon
Fusion or no Fusion After Decompression of the Spinal Cord in Patients With Degenerative Cervical Myelopathy Recruiting
Clinical Investigation of Proton Treatment in Hodgkin Lymphoma Patients - PRO-Hodgkin Recruiting

Other trials for the same condition

Acute Achilles Tendon Rupture - Choice of Treatment Based on Ultrasound Findings Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06261411 on ClinicalTrials.gov ↗ ← All trials in Sweden